X4 Pharmaceuticals, Inc. (XFOR) News
Filter XFOR News Items
XFOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XFOR News Highlights
- XFOR's 30 day story count now stands at 3.
- Over the past 14 days, the trend for XFOR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about XFOR are RARE, DRUG and LINK.
Latest XFOR News From Around the Web
Below are the latest news stories about X4 PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XFOR as an investment opportunity.
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare ConferenceBOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City, from September 26-28, 2023. Details are as follows:Conference: Cantor Global Healthcare ConferenceDate: Tuesday, September 26, 2023Time: 4:55 PM ETWebcast Link About X4 Pharmaceut |
X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceBOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York City. Details are as follows:Conference: Morgan Stanley 21st Annual Global Healthcare ConferenceDate: Wednesday, September 13, 2023Time: 7:30 AM ETWebcast Link About X4 Pharmac |
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM SyndromeSubmission supported by positive results from global, pivotal 4WHIM Phase 3 clinical trialBOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for the approval of once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (Warts, Hypogammaglobuline |
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced that, effective on August 31, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards |
XFOR: NDA for Mavorixafor in WHIM Syndrome in Early 2H23…By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update NDA on Track for Mavorixafor for WHIM in Early 2H23 On August 10, 2023, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) provided an update on mavorixafor, the company’s lead development candidate that is a small molecule antagonist of chemokine receptor CXCR4. Mavorixafor is able to mobilize mature, functional white blood |
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical ProgramSubmission of first U.S. New Drug Application for mavorixafor in WHIM syndrome on track for early 2H 2023 Emerging data from ongoing Phase 2 trial in certain chronic neutropenic disorders show mavorixafor durably increased neutrophil counts and enabled reductions in G-CSF dosing New market research confirms significant initial target population for mavorixafor given high unmet needs within U.S. chronic neutropenia (CN) market Plans underway for initiation of Phase 3 trial in certain chronic neut |
X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical OfficerBOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that Christophe Arbet-Engels, MD, PhD, will be joining the company as its new Chief Medical Officer, bringing more than 25 years’ experience in strategic global drug development across a wide range of therapeutic areas including rare and orphan diseases. “We are thr |
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules CapitalBOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced that it drew down $22.5 million upon the transaction’s closing. “This expanded loan facility creates significant financial flexibility for X4 a |
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the second quarter ended June 30, 2023, and providing corporate and clinical program updates on Thursday, August 10, 2023. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The confer |
XFOR: Initiating Coverage of X4 Pharmaceuticals; Investing on More Than Just a WHIM…By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Initiating Coverage We are initiating coverage of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) with a valuation of $4.50. X4 is a biopharmaceutical company developing therapies for rare diseases with a focus on those arising from a dysfunction of the immune system. The company’s lead development candidate, mavorixafor, is a small |